ArticleOncogene2026
The splicing factor hnRNPA1 promotes osimertinib resistance in lung adenocarcinoma by regulating NEDD4L alternative splicing.
Article in Oncogene, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
Abstract
Resistance to osimertinib in lung adenocarcinoma presents a significant hurdle in contemporary lung cancer therapy, with splicing dysregulation being instrumental in tumorigenesis and progression. The mechanism via which alternate splicing facilitates osimertinib resistance in lung cancer is still ambiguous. We aimed to examine the pivotal function of the splicing factor hnRNPA1 in osimertinib resistance in lung cancer. The impact of hnRNPA1 on osimertinib resistance in lung cancer was confirmed by small interfering RNA and CDX models. RNA-seq, RIP, CLIP-qPCR, and COIP methodologies were utilized to examine the mechanistic role of hnRNPA1 in osimertinib resistance in lung cancer. Furthermore, virtual docking was employed to evaluate natural small-molecule drugs that target hnRNPA1.Elevated levels of the splicing factor hnRNPA1 were detected in lung adenocarcinoma cells exhibiting resistance to osimertinib, and the silencing of hnRNPA1 enhanced the sensitivity of these resistant cells to osimertinib. Mechanistically, hnRNPA1 governs multiple splicing events linked to cancer, notably the splicing of NEDD4L. Decreased hnRNPA1 enhances the generation of short NEDD4L splice variants, resulting in the ubiquitination and degradation of EGFR, which sensitizes resistant cells to osimertinib. Moreover, hnRNPA1 undergoes methylation modification by PRMT7, which facilitates splicing activities. The research elucidated the mechanism responsible for aberrant splicing in osimertinib resistance in lung cancer and identified hnRNPA1 as a prospective therapeutic target for counteracting this resistance.
Indexed as
Identifiers
42321531What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.